Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Roche, Catalent and Novo Holdings A/S
Roche comes out against allowing takeover of drug manufacturer Catalent
The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by Novo Nordisk's controlling shareholder, as it could hit competition in the booming weight-loss drug industry.
Roche CEO says Novo's Catalent buyout 'could be a problem' for smaller drugmakers
The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief commercial rival, Eli Lilly, but also companies like Viking Therapeutics, Pfizer, Roche and AstraZeneca, who are working on their own metabolic offerings.
Roche Beats Q3 Sales Estimates as CEO Voices Opposition to Novo Holdings’ Catalent Buyout
Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by strong performance of its multiple sclerosis therapy Ocrevus and eye injection Vabysmo.
Roche Comes Out Against Clearing Takeover of Drug Manufacturer Catalent
FRANKFURT (Reuters) - The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer
Catalent
by Novo Nordisk's controlling shareholder, citing harm to industry peers. "It's not a problem for us ...
Roche CEO says antitrust regulators should block Catalent sale to Novo Foundation
The CEO of Swiss pharmaceuticals behemoth Roche (OTCQX:RHHBY) said he believes antitrust regulators should not allow Novo Nordisk Foundation's to purchase Catalent (NYSE:CTLT). "It's not a problem for us,
16h
on MSN
Roche CEO says antitrust regulators should block Catalent sale to Novo Holdings (update)
Adds Catalent response. The CEO of Swiss pharmaceuticals behemoth Roche (OTCQX:RHHBY) said he believes antitrust regulators ...
10h
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
On Wednesday, Roche Holdings AG (OTC:RHHBY) released its third-quarter sales report. Sales increased 9% year over year to ...
2d
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout
Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is ...
bovnews
16h
The Catalent Inc Stock Thriller: Decoding the Mystery Behind CTLT’s Recent Movements
On Tuesday, Catalent Inc (CTLT) stock saw a decline, ending the day at $59.92 which represents a decrease of $-0.26 or -0.43% from the prior close of $60.18. The stock opened at $60.14 and touched a ...
2d
Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, ...
STAT
2d
Catalent tries to reassure customers about its deal with Novo Holdings
Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...
2d
Catalent Issues Open Letter To Customers; To Operate As Full-service CDMO Under Novo
Catalent, Inc. (CTLT) said, following the closing of transaction, as a private company under Novo Holdings' ownership, Catalent will ...
PharmTech
2d
AAPS PharmSci 360: LBFs and Tackling Oral Biologic Formulations
At AAPS PharmSci 360, Karunakar Sukuru, RPh, PhD, the global vice-president-Rx Product Development, Pharma and Consumer ...
STAT
2d
Pharmalittle: We’re reading about ballooning 340B drug sales, Catalent reassuring customers, and more
Confounding data from a Pfizer clinical trial have rattled the field of gene therapy for Duchenne muscular dystrophy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Roche
Novo Holdings
Eli Lilly and Company
CTLT
Feedback